An economic analysis of TNF-α antagonists for rheumatoid arthritis in Polish settings;Analiza opłacalnos- Ci stosowania inhibitoro- w TNF-α w leczeniu reumatoidalnego zapalenia stawo- w w warunkach polskich

Reumatologia

Volumn 45, Issue 5, 2007, Pages 268-275

  Kaczor, Marcin P ^a,b   Wójcik, Rafał ^a  

^a Centrum Gastroenterologii W Krakowie   (Poland)

^b NONE   (Poland)

Author keywords

Antagonists; Economic analysis; Etanercept; Rheumatoid arthritis; TNF

Indexed keywords

EID: 36549084573     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Filipowicz-Sosnowska A. Reumatoidalne zapalenie stawów. W: Choroby wewnetrzne. Szczeklik A (red.). Wyd. 1. Vol. 2. Medycyna Praktyczna, Kraków 2006; 1645-1657.
2. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41: 793-800.
3. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: iii-iv, xi-xiii, 1-229.
4. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002; 29: 1156-1165.
5. Coyle D, Judd M, Blumenauer B, et al. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation. Ottawa: Canadian Coordinating Office for Health Technology Assessment Technology Report 2006; 64.
6. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003; 42: 326-335.
7. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005; 64: 1174-1179.
8. Tanno M, Nakamura I, Ito K, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006; 16: 77-84.
9. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113: 400-408.
10. Welsing PM, Severens JL, Hartman M, et al. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004; 51: 964-973.
11. Bansback NJ, Brennan A Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005; 64: 995-1002.
12. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004; 43: 62-72.
13. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologies Registry. Rheumatology (Oxford) 2007; 46: 1345-1354.
14. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002; 6: 1-110.
15. Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004; 8: iii, 1-91.
16. Agencja Oceny Technologii Medycznych. Wytyczne przeprowadzania Oceny Technologii Medycznych (HTA). Kraków - Warszawa 2007; dostepne w Internecie: http://www.aotm.gov.pl/pliki/spr/pł/ Wytyczne%20HTA%20w%20AOTM.pdf (data ostatniego dostepu: październik 2007).
17. Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39: 975-981.
18. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-798.
19. Edwards CJ, Arden NK, Fisher D, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005; 44: 1394-1398.
20. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. Health Qual Life Outcomes 2003; 1: 20.
21. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167-178.
22. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective; Evidence from the EuroQol BIOMED Research Programme. Brooks R, Rabin R, de Charro F (ed.). Kluwer Academic Publishers, Dordrecht 2003.
23. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003; 4: 222-231.
24. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-494.